progression-free survival
Objectives: To evaluate the progression-free survival (PFS) and some related factors in the first-line erlotinib treatment for advanced non- small lung cancer (NSCLC) patients with EGFR mutations.
Objectives : To evaluate the progression-free survival ( PFS ) and some related factors in the first-line erlotinib treatment for advanced non- small lung cancer ( NSCLC ) patients with EGFR mutations .